Business
REGENXBIO Announces Leadership Transition
Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the
About this update from Regenxbio Inc.
[{"type":"text","content":"Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO's Lead Independent Director, a role previously held by Jerry Karabelas, Ph.D. Dr. Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board.\nMr. Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience. As the Chief Operating Officer (COO) at REGENXBIO since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 and served as the Company's Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO at Human Genome Sciences (HGS), where he led the integration of HGS into GSK.\n\"I am honored to serve as REGENXBIO's next President and CEO,\" said Mr. Simpson. \"I have been a part of shaping and leading our programs from preclinical to pivotal stages with Ken, and today, our AAV Therapeutics platform is well-positioned to make a meaningful impact. I look forward to our exciting next chapter as I continue to work with Ken and the rest of REGENXBIO's seasoned management team and Board to further advance our pipeline, drive the commercialization and scale of our business and deliver value for patients, shareholders and our other stakeholders.\"\n\"Leading REGENXBIO since our founding in 2009 has been a privilege,\" said Mr. Mills. \"We have built the Company into a leader in gene therapy medicines wi...